Panel endorses Merck's anti-clotting drug

Share this article:

Advising the FDA to “do its due diligence” about bleeding risk, an FDA panel voted 10-1 in favor of Merck's anti-clotting drug vorapaxar, which would have the brand name Zontivity, Reuters reports. The panel and Merck want to limit the drug's use to heart attack patients without a stroke history, because of an increased bleeding risk among stroke patients.

Aspirin, and Bristol-Myers Squibb's now off-patent Plavix (clopidogrel) seek the same goal—to prevent clots—but Reuters notes Merck's potential market peer works differently, by inhibiting a PAR-1 receptor.

The panel also says the drug should come with a weight minimum because lighter patients appear to be at a higher risk for bleeds.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.